Press coverage about Concert Pharmaceuticals (NASDAQ:CNCE) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Concert Pharmaceuticals earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.5523153081493 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Concert Pharmaceuticals Inc (CNCE) Expected to Announce Quarterly Sales of $8.10 Million (americanbankingnews.com)
- Celldex Therapeutics (CLDX) vs. Concert Pharmaceuticals (CNCE) Financial Contrast (americanbankingnews.com)
- ETFs with exposure to Concert Pharmaceuticals, Inc. : December 1, 2017 (finance.yahoo.com)
- Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017 (finance.yahoo.com)
Concert Pharmaceuticals (NASDAQ:CNCE) opened at $23.85 on Monday. Concert Pharmaceuticals has a 52 week low of $7.11 and a 52 week high of $24.04.
In other news, insider Value Fund L. P. Biotechnology acquired 331,916 shares of the business’s stock in a transaction that occurred on Thursday, October 19th. The shares were bought at an average price of $15.84 per share, with a total value of $5,257,549.44. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Ryan Lynch sold 3,500 shares of the firm’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $14.51, for a total value of $50,785.00. Following the sale, the insider now directly owns 9,500 shares in the company, valued at approximately $137,845. The disclosure for this sale can be found here. Company insiders own 10.10% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Concert Pharmaceuticals (CNCE) Getting Somewhat Positive Press Coverage, Study Finds” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2017/12/04/concert-pharmaceuticals-cnce-getting-somewhat-positive-press-coverage-study-finds.html.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
What are top analysts saying about Concert Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Concert Pharmaceuticals Inc and related companies.